• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tokai Pharmaceuticals

edit

Tokai was founded by Apple Tree Partners to in-license and develop endocrine-based therapies for major diseases.

The company’s primary focus is on its proprietary Specific Androgen Receptor Modulator/Lyase Inhibitor (TOK-001) for Castration Resistant Prostate Cancer (CRPC).

Milestones

edit

• 
  Tokai Pharmaceuticals added Jodie Morrison as COO and Vice President of Clinical Affairs.
  Posted 9/20/11 at 6:24pm
• 
  Tokai Pharmaceuticals added Martin D. Williams as President and CEO.
  Posted 9/20/11 at 6:24pm
• 
  Tokai Pharmaceuticals added Seth Harrison as Board of Directors.
  Posted 6/17/09 at 1:00pm
• 
  Tokai Pharmaceuticals received $23M in Series D funding. (9/20/11)
  Posted 9/20/11 at 4:53am via businesswire.com
• 
  Tokai Pharmaceuticals received $22M in Series D funding. (6/9/09)
  Posted 6/17/09 at 1:00pm via onbiovc.com

Videos

Screenshots

edit

Above: Tokai Pharmaceuticals Screenshot -- #1
Uploaded: 6/17/09

Sources

1. Tokai Pharmaceuticals, Inc.: Series D $22M (onbiovc.com) [edit]
2. Tokai Pharmaceuticals Raises $23 Million in Funding (eon.businesswire.com) [edit]